DECLOMYCIN (demeclocycline hydrochloride) by Pfizer is clinical pharmacology pharmacokinetics the absorption of demeclocycline is slower than that of tetracycline. Approved for infections caused by the following gram-negative microorganisms, bacteriologic testing indicates appropriate susceptibility to the drug: escherichia coli, infections caused by the following gram-positive microorganisms and 7 more indications. First approved in 1964.
Drug data last refreshed 9h ago · AI intelligence enriched 6d ago
DECLOMYCIN (demeclocycline hydrochloride) is an oral tetracycline antibiotic approved in 1964 for treatment of bacterial infections including rickettsial diseases, gram-positive and gram-negative infections. It works by inhibiting bacterial protein synthesis, exerting bacteriostatic activity against a broad spectrum of organisms. Demeclocycline has slower absorption than tetracycline with a serum half-life of 10-16 hours and reduced renal clearance.
Approaching loss of exclusivity with stable but limited competitive pressure (30%), indicating a mature brand with declining career growth opportunities for commercial teams.
CLINICAL PHARMACOLOGY Pharmacokinetics The absorption of demeclocycline is slower than that of tetracycline. The time to reach the peak concentration is about 4 hours. After a 150 mg oral dose of demeclocycline tablet, the mean concentrations at 1 hour and 3 hours are 0.46 and 1.22 mcg/mL (n = 6),…
Worked on DECLOMYCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
DECLOMYCIN offers minimal career advancement potential as a mature, generic-competitive antibiotic approaching LOE with zero linked job postings. Positions on this product focus on defending market share and compliance rather than growth, expansion, or innovation, making it unsuitable for career-focused pharma professionals.